AR065179A1 - PROGESTERONE FOR THE TREATMENT OR PREVENTION OF SPONTANEOUS PREMATURE BIRTH - Google Patents

PROGESTERONE FOR THE TREATMENT OR PREVENTION OF SPONTANEOUS PREMATURE BIRTH

Info

Publication number
AR065179A1
AR065179A1 ARP080100476A ARP080100476A AR065179A1 AR 065179 A1 AR065179 A1 AR 065179A1 AR P080100476 A ARP080100476 A AR P080100476A AR P080100476 A ARP080100476 A AR P080100476A AR 065179 A1 AR065179 A1 AR 065179A1
Authority
AR
Argentina
Prior art keywords
progesterone
treatment
prevention
premature birth
spontaneous premature
Prior art date
Application number
ARP080100476A
Other languages
Spanish (es)
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39301249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065179(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of AR065179A1 publication Critical patent/AR065179A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método para tratar o prevenir el parto prematuro espontáneo en mujeres embarazadas y mejorar la morbilidad y mortalidad neonatal. El método incluye administrar a una mujer embarazada que lo requiere una cantidad efectiva de progesterona suficiente para prolongar la gestacion al minimizar el acortamiento o borramiento de su cuello uterino. Se ha demostrado clínicamente que el tratamiento y profilaxis con progesterona en una mujer embarazada que tiene síntomas de cuello uterino corto aumenta la salud neonatal.A method to treat or prevent spontaneous premature delivery in pregnant women and improve neonatal morbidity and mortality. The method includes administering to a pregnant woman who requires an effective amount of progesterone sufficient to prolong pregnancy by minimizing the shortening or erasure of her cervix. It has been clinically proven that treatment and progesterone prophylaxis in a pregnant woman who has short cervical symptoms increases neonatal health.

ARP080100476A 2007-02-06 2008-02-05 PROGESTERONE FOR THE TREATMENT OR PREVENTION OF SPONTANEOUS PREMATURE BIRTH AR065179A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88848007P 2007-02-06 2007-02-06
US97366707P 2007-09-19 2007-09-19
US12/024,756 US8828981B2 (en) 2007-02-06 2008-02-01 Progesterone for the treatment or prevention of spontaneous preterm birth

Publications (1)

Publication Number Publication Date
AR065179A1 true AR065179A1 (en) 2009-05-20

Family

ID=39301249

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100476A AR065179A1 (en) 2007-02-06 2008-02-05 PROGESTERONE FOR THE TREATMENT OR PREVENTION OF SPONTANEOUS PREMATURE BIRTH

Country Status (24)

Country Link
US (2) US8828981B2 (en)
EP (1) EP2117554B1 (en)
JP (2) JP5580601B2 (en)
KR (1) KR101546101B1 (en)
AR (1) AR065179A1 (en)
AU (1) AU2008212724A1 (en)
BR (1) BRPI0807203A2 (en)
CA (1) CA2677354C (en)
CL (1) CL2008000375A1 (en)
CO (1) CO6220941A2 (en)
CR (1) CR10985A (en)
ES (1) ES2596803T3 (en)
GE (1) GEP20135727B (en)
HK (1) HK1136975A1 (en)
IL (1) IL200272A (en)
MA (1) MA31200B1 (en)
ME (1) ME00930B (en)
MX (1) MX2009008409A (en)
MY (1) MY184866A (en)
NZ (1) NZ579114A (en)
PE (1) PE20081738A1 (en)
RU (1) RU2524617C2 (en)
TW (1) TWI471135B (en)
WO (1) WO2008096122A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2533915C (en) 2002-08-13 2020-09-22 N-Dia, Inc. Devices and methods for detecting amniotic fluid in vaginal secretions
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
SI2359807T1 (en) 2008-02-04 2017-10-30 Ferring B.V. Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
WO2010034779A2 (en) 2008-09-24 2010-04-01 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Composition and method for treatment of preterm labor
GB0905964D0 (en) * 2009-04-06 2009-05-20 King S College London Marker
WO2011079047A1 (en) * 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
CA2789238C (en) * 2010-03-09 2020-05-12 Dignity Health Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
CA2813433C (en) * 2010-10-27 2019-08-20 Dignity Health Trimegestone (tmg) for treatment of preterm birth
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
DE102012009057A1 (en) * 2012-05-09 2013-11-14 Dr. Arabin GmbH & Co. KG Rotational pessary made from a polymer comprises an active substance against premature births
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014107373A1 (en) * 2013-01-02 2014-07-10 N-Dia, Inc. Methods for predicting time-to-delivery in pregnant women
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
DK2982352T3 (en) * 2014-06-28 2018-11-26 Laboratorios Andromaco S A CERVICALLY PESSAR CONTAINING PROGESTERON FOR EXTENDED, LONG AND CONTINUOUS RELEASE USED TO PREVENT EARLY BIRTHS
KR20170040209A (en) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 Transdermal cream
KR101726488B1 (en) 2015-02-23 2017-04-13 이화여자대학교 산학협력단 Composition for the treatment of pregnancy-related diseases comprising the extracellular vesicles derived from Bacillus spp.
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
CN107847506A (en) 2015-06-22 2018-03-27 来普卡公司 Orally administered composition and correlation technique containing 17 Gestageno Gadors
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
US11029318B2 (en) * 2015-08-28 2021-06-08 Kypha, Inc. Methods for predicting and treating patients with increased risk of adverse pregnancy outcome
US10556922B2 (en) 2015-09-29 2020-02-11 Amag Pharmaceuticals, Inc. Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017200987A1 (en) * 2016-05-16 2017-11-23 Amag Pharmaceuticals, Inc. Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same
US10935555B2 (en) 2016-12-22 2021-03-02 Qiagen Sciences, Llc Determining candidate for induction of labor
US10656164B2 (en) 2016-12-22 2020-05-19 Qiagen Sciences, Llc Screening asymptomatic pregnant woman for preterm birth
JP2018140172A (en) * 2017-02-28 2018-09-13 株式会社Ｎｔｔドコモ Data collection device and data collection method
US11207509B2 (en) 2017-06-15 2021-12-28 Wiesman Holdings, LLC Method and device for delivery of a solution into a body orifice
RU2657772C1 (en) * 2017-07-06 2018-06-15 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский институт акушерства и гинекологии" Министерства здравоохранения Московской области Method of preventing gestational complications in pregnant women with epilepsy
US20190038637A1 (en) * 2017-08-05 2019-02-07 Eric Marchewitz Use of Hydroxyprogesterone Derivatives for Enhanced Health and Physical Performance II
AU2018357888A1 (en) * 2017-10-30 2020-05-28 Carmentix Pte. Ltd. Biomarkers of preterm birth
RU2692932C2 (en) * 2017-11-07 2019-06-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) BIOCATALYST FOR PRODUCING 11α-ACETOXYPROGESTERONE
USD918388S1 (en) 2018-06-15 2021-05-04 Wiesman Holdings, LLC Solution diffusing head
JP7301326B2 (en) * 2018-10-16 2023-07-03 公立大学法人横浜市立大学 Neonatal to childhood-onset cerebrovascular disease or method for detecting carriers thereof
KR102157438B1 (en) * 2019-04-16 2020-09-21 고려대학교 산학협력단 Method and Kit for diagnosing preterm birth
US20220339176A1 (en) * 2019-09-23 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation
WO2021068239A1 (en) 2019-10-12 2021-04-15 国家卫生健康委科学技术研究所 Vaginal slow-release administration system for luteal support, preparation method therefor and use thereof
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
KR102482468B1 (en) * 2020-08-11 2022-12-28 연세대학교 산학협력단 Methods for providing information about preterm birth and device using the same
US20220072008A1 (en) * 2020-09-08 2022-03-10 Cedars-Sinai Medical Center Method of using progesterone receptor agonists for the treatment of covid-19
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
DE4229820C2 (en) 1992-09-07 1998-12-03 Jenapharm Gmbh Progestogen-based pharmaceutical preparation
US5830848A (en) 1992-10-09 1998-11-03 The Regents Of The University Of California Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
US5948762A (en) 1993-07-16 1999-09-07 Schering Aktiengesellschaft Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor or a nitric oxide inhibitor
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
HUP9800826A3 (en) 1995-03-14 1998-08-28 Schering Ag Use of nitric oxide donors or nitric oxide inhibitors for preparing medicaments for regulating cervical dilatation and extensibility
US5910482A (en) 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
US5744463A (en) * 1996-06-03 1998-04-28 Bair; Glenn O. Treatment of side effects of progestins and progesterone analogues used for birth control
US5985861A (en) 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
DE69819748T2 (en) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. MEDICINES FOR TREATING DYSMENORRHEA AND PREVIOUS BLIES
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6306914B1 (en) 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
US20020031513A1 (en) 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US5941888A (en) * 1998-02-18 1999-08-24 Target Therapeutics, Inc. Vaso-occlusive member assembly with multiple detaching points
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
AU5683900A (en) 1999-06-21 2001-01-09 Columbia Laboratories (Bermuda) Limited Programming ovulation
US6375970B1 (en) * 1999-07-07 2002-04-23 Andre Bieniarz Methods and materials for preterm birth prevention
JP2005503389A (en) 2001-08-31 2005-02-03 シエーリング オサケユイチア Drug delivery system
FR2832065B1 (en) * 2001-11-13 2004-11-05 Besins Int Belgique PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE, PREPARATION METHOD THEREOF AND USES THEREOF
FR2842108B1 (en) 2002-07-09 2008-05-02 Effik COMPOUNDS BASED ON HORMONE AND NITROGEN MONOXIDE AND THEIR USE IN OBSTETRICS AND GYNECOLOGY
WO2004071427A2 (en) 2003-02-06 2004-08-26 Adeza Biomedical Corporation Screening and treatment methods for prevention of preterm delivery
TW200626161A (en) 2004-10-07 2006-08-01 Duramed Pharmaceuticals Inc Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
EA015155B1 (en) 2005-05-26 2011-06-30 Тева Вуменс Хелс, Инк. Oral dosage forms comprising progesterone and methods of making and using the same
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth

Also Published As

Publication number Publication date
MY184866A (en) 2021-04-28
US20090264395A1 (en) 2009-10-22
CL2008000375A1 (en) 2008-05-30
TW200902030A (en) 2009-01-16
IL200272A0 (en) 2010-04-29
MA31200B1 (en) 2010-02-01
RU2009133315A (en) 2011-03-20
JP2010518058A (en) 2010-05-27
EP2117554B1 (en) 2016-07-13
HK1136975A1 (en) 2010-07-16
PE20081738A1 (en) 2008-11-20
US20080188829A1 (en) 2008-08-07
RU2524617C2 (en) 2014-07-27
WO2008096122A2 (en) 2008-08-14
EP2117554A2 (en) 2009-11-18
JP5580601B2 (en) 2014-08-27
CR10985A (en) 2009-10-23
US7884093B2 (en) 2011-02-08
ES2596803T3 (en) 2017-01-12
WO2008096122A3 (en) 2009-02-26
CO6220941A2 (en) 2010-11-19
JP2014058529A (en) 2014-04-03
GEP20135727B (en) 2013-01-25
NZ579114A (en) 2012-07-27
IL200272A (en) 2014-02-27
KR101546101B1 (en) 2015-08-20
ME00930B (en) 2012-03-20
CA2677354C (en) 2015-07-07
TWI471135B (en) 2015-02-01
BRPI0807203A2 (en) 2014-07-22
MX2009008409A (en) 2009-09-16
AU2008212724A1 (en) 2008-08-14
KR20090123875A (en) 2009-12-02
US8828981B2 (en) 2014-09-09
CA2677354A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
AR065179A1 (en) PROGESTERONE FOR THE TREATMENT OR PREVENTION OF SPONTANEOUS PREMATURE BIRTH
AR115939A2 (en) COMPOSITION CONTAINING ULTRA-MICRONIZED PALMITOYL-ETHANOLAMIDE
EP2381957A4 (en) Therapeutic modulation of vaginal epithelium boundary lubrication
DOP2010000141A (en) BREAST CANCER TREATMENT WITH A PARP INHIBITOR ONLY OR IN COMBINATION WITH ANTI-TUMOR AGENTS
BRPI0517799A (en) composition to facilitate human childbirth
ECSP088390A (en) METHOD FOR PREVENTIVE HORMONAL ANTI-CONCEPTION UNDER DEMAND
ECSP13012650A (en) METHODS AND COMPOSITIONS TO TREAT DIARRHEA ASSOCIATED WITH HIV
American College of Obstetricians and Gynecologists ACOG Committee opinion no. 550: maternal-fetal surgery for myelomeningocele
MY181349A (en) Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
BR112014026340A2 (en) hallux valgus sandal
CO2017003263A2 (en) Pharmaceutical composition based on anamorelin having activity on cachexia caused by cancer
CO7111317A2 (en) Method for the treatment of gynecological diseases
ECSP12011629A (en) FULVESTRANT IN A DOSE OF 500 MG FOR THE TREATMENT OF ADVANCED BREAST CANCER
UA101474C2 (en) Use of a progesterone in the manufacture of a medicament
TN2015000197A1 (en) Use and application regimen of a pharmaceutical composition containing levonorgestrel and a cox inhibitor for on-demand contraception
MX2015014222A (en) Pharmaceutical compositions comprising kisspeptin or derivatives thereof.
AR057755A1 (en) METHOD FOR TREATMENT OF PLACENTARY MAMMALS PARTNERS IN ORDER TO REDUCE MATERNAL AND / OR UTERINE EXHAUSTION
BR112018011483A2 (en) methods and pharmaceutical compositions with vaginally inserted estradiol
UA41294U (en) Method for treating asherman syndrome in women of reproductive age
Mahto et al. Management of Dystocia due to Uterine Torsion in a Doe
Alkareem et al. Comparison of Different Medical Treatment of Missed Abortion
市田美保 et al. No increase in breast cancer risk in Japanese women taking oral contraceptives: A case-control study investigating reproductive, menstrual and familial risk factors for breast cancer.
MD3645G2 (en) Method of treating uterine hypotonic postpartum hemorrhages
MD335Z (en) Method for preparing the neck of uterus for induction of delivery in pregnants with prolonged pregnancy
AR076016A1 (en) DOMPERIDONE AT A LOW DAILY DOSE FOR USE IN THE TREATMENT OR PREVENTION OF AN ILLNESS ASSOCIATED WITH AN ALTERATION OF THE IMMUNE RESPONSE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure